Business
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores Entera's mission to democratize anabolic treatment for osteoporosis patients and caregivers globally JERUSALEM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, is thrille
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio","displaySize":"","headline":null,"caption":"Entera Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":237,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PKeefwE624EAwJoXBY3bXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515","width":237,"height":138}},"lazy":false},{"type":"text","content":"FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613","length":196,"tagName":"p"},{"type":"text","content":"Underscores Entera's mission to democratize anabolic treatment for osteoporosis patients and caregivers globally","length":116,"tagName":"p"},{"type":"text","content":"JERUSALEM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, is thrilled to congratulate the FNIH-ASBMR-SABRE1 team following the Food and Drug Administration (FDA) broad qualification of total hip bone mineral density (BMD) as a validated regulatory endpoint for novel drugs in development for post-menopausal women at risk for osteoporotic fracture.","length":494,"tagName":"p"},{"type":"text","content":""Since mid-2022, Entera has been steadfast in our public advocacy and support of the SABRE initiative and the FDA's plan to implement this significant regulatory reform," said Miranda Toledano, Chief Executive Officer of Entera. “Over 200 million women globally are estimated to have osteoporosis and remain vastly undertreated, yet no new drug for osteoporosis has been approved by FDA since 2019. Innovation has stalled largely due to the size, duration, cost and ethical constraints associated with fracture endpoint studies. In the last three years, we have been privileged to forge meaningful ties and build an ecosystem of patients, clinicians, and change agents committed to addressing this significantly underserved area," continued Toledano. "In July 2025, Entera was the first company to receive FDA alignment that a single Phase 3 study with total h...